John P Moore1, Daniel R Kuritzkes. 1. Weill Medical College of Cornell University, New York, NY 10065, USA. jpm2003@med.cornell.edu
Abstract
PURPOSE OF REVIEW: Small molecule inhibitors targeting the CCR5 coreceptor represent a new class of drugs for treating HIV-1 infection. Maraviroc has received regulatory approvals, and vicriviroc is in phase 3 trials. Understanding how resistance to these drugs develops and is diagnosed is essential to guide clinical practice. We review what has been learned from in-vitro resistance studies, and how this relates to what is being seen, or can be anticipated, in clinical studies. RECENT FINDINGS: The principal resistance pathway in vitro involves continued use of CCR5 in an inhibitor-insensitive manner; the resistant viruses recognize the inhibitor-CCR5 complex, as well as free CCR5. Switching to use the CXCR4 coreceptor is rare. The principal genetic pathway involves accumulating 2-4 sequence changes in the gp120 V3 region, but a non-V3 pathway is also known. The limited information available from clinical studies suggests that a similar escape process is followed in vivo. However, the most common change associated with virologic failure involves expansion of pre-existing, CXCR4-using viruses that are insensitive to CCR5 inhibitors. SUMMARY: HIV-1 escapes small molecule CCR5 inhibitors by continuing to use CCR5 in an inhibitor-insensitive manner, or evades them by expanding naturally insensitive, CXCR4-using variants.
PURPOSE OF REVIEW: Small molecule inhibitors targeting the CCR5 coreceptor represent a new class of drugs for treating HIV-1 infection. Maraviroc has received regulatory approvals, and vicriviroc is in phase 3 trials. Understanding how resistance to these drugs develops and is diagnosed is essential to guide clinical practice. We review what has been learned from in-vitro resistance studies, and how this relates to what is being seen, or can be anticipated, in clinical studies. RECENT FINDINGS: The principal resistance pathway in vitro involves continued use of CCR5 in an inhibitor-insensitive manner; the resistant viruses recognize the inhibitor-CCR5 complex, as well as free CCR5. Switching to use the CXCR4 coreceptor is rare. The principal genetic pathway involves accumulating 2-4 sequence changes in the gp120 V3 region, but a non-V3 pathway is also known. The limited information available from clinical studies suggests that a similar escape process is followed in vivo. However, the most common change associated with virologic failure involves expansion of pre-existing, CXCR4-using viruses that are insensitive to CCR5 inhibitors. SUMMARY:HIV-1 escapes small molecule CCR5 inhibitors by continuing to use CCR5 in an inhibitor-insensitive manner, or evades them by expanding naturally insensitive, CXCR4-using variants.
Authors: Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos Journal: Antimicrob Agents Chemother Date: 2006-11-20 Impact factor: 5.191
Authors: Christina M R Kitchen; Jing Lu; Marc A Suchard; Rebecca Hoh; Jeffrey N Martin; Daniel R Kuritzkes; Steven G Deeks Journal: AIDS Res Hum Retroviruses Date: 2006-12 Impact factor: 2.205
Authors: Christoph Seibert; Weiwen Ying; Svetlana Gavrilov; Fotini Tsamis; Shawn E Kuhmann; Anandan Palani; Jayaram R Tagat; John W Clader; Stuart W McCombie; Bahige M Baroudy; Steven O Smith; Tatjana Dragic; John P Moore; Thomas P Sakmar Journal: Virology Date: 2006-02-21 Impact factor: 3.616
Authors: Ronald S Veazey; Per Johan Klasse; Susan M Schader; Qinxue Hu; Thomas J Ketas; Min Lu; Preston A Marx; Jason Dufour; Richard J Colonno; Robin J Shattock; Martin S Springer; John P Moore Journal: Nature Date: 2005-10-30 Impact factor: 49.962
Authors: Ronald S Veazey; Martin S Springer; Preston A Marx; Jason Dufour; Per Johan Klasse; John P Moore Journal: Nat Med Date: 2005-11-06 Impact factor: 53.440
Authors: Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros Journal: J Virol Date: 2006-12-20 Impact factor: 5.103
Authors: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Pavel Pugach; Andre J Marozsan; Thomas J Ketas; Elissa L Landes; John P Moore; Shawn E Kuhmann Journal: Virology Date: 2006-12-12 Impact factor: 3.616
Authors: P Recordon-Pinson; S Raymond; P Bellecave; A G Marcelin; C Soulie; D Descamps; V Calvez; P R Harrigan; H Fleury; J Izopet; B Masquelier Journal: Antimicrob Agents Chemother Date: 2012-12-03 Impact factor: 5.191
Authors: Robert A Ogert; Lei Ba; Yan Hou; Catherine Buontempo; Ping Qiu; Jose Duca; Nicholas Murgolo; Peter Buontempo; Robert Ralston; John A Howe Journal: J Virol Date: 2009-09-23 Impact factor: 5.103
Authors: John C Tilton; Heather Amrine-Madsen; John L Miamidian; Kathryn M Kitrinos; Jennifer Pfaff; James F Demarest; Neelanjana Ray; Jerry L Jeffrey; Celia C Labranche; Robert W Doms Journal: AIDS Res Hum Retroviruses Date: 2010-01 Impact factor: 2.205